The Etanercept Biosimilar Market Size is valued at XX Million in 2024 and is predicted to reach XX Million by the year 2034 at an 17.8% CAGR during the forecast period for 2025-2034.
Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, an important inflammatory disease mediator in various articular diseases. Etanercept was the first tumour necrosis factor-alpha (TNF-α) inhibitor approved for the treatment of rheumatoid arthritis. It is also approved for the treatment of juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Etanercept competitively inhibits the binding of TNF to cell surface receptors and thus makes TNF biologically inactive. By doing so, the drug inhibits the pro-inflammatory effects of TNF and thereby leads in a reduction of joint inflammation. Etanercept was developed and marketed by Amgen and Pfizer. The drug was approved by the U.S. Food Drug and Administration in November 1998. It was approved in Europe by European Medicines Agency in February 2000. It is marketed under the trade name of ‘Enbrel’.
Expiration of patent and near-term expiration of patent has led to the entry of biosimilar into the market. The patent of Enbrel is expired in Europe in August 2015 and will expire in the U.S. in November 2028. Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. Reducing treatment cost is the principal attraction factor for the growth of etanercept biosimilars market. Thus many of biosimilar of etanercept are currently approved and some are in development phase which are expected to come into the market during forecast period. Introduction to biosimilars, increase in incidence and prevalence rate of various articular diseases, and rising demand for cost effective alternatives are the factors boosted the growth of etanercept biosimilar market. However, stringent regulatory process for the approval of etanercept biosimilar and complicated manufacturing process are the major restrain factors for the growth of the etanercept biosimilar market.
The global etanercept biosimilar market is segmented on the basis of application, distribution channel and geography. Based on the application global etanercept biosimilar market is segmented into rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Rheumatoid arthritis segment is expected to grow at higher pace during the forecast period owing to increasing incidence and prevalence rate. Based on distribution channel the global etanercept biosimilar market is segmented as hospital pharmacy, online pharmacy and others. Online pharmacy segment is expected to grow during forecast period due to increase in number of internet users and ease of use.
Geographically, the global etanercept biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by Asia Pacific is major contributor for the global etanercept biosimilar market. This is because early patent expiry, entry of etanercept biosimilars, strong clinical pipeline, increasing research and drug development activities, presence of major players, and developing healthcare infrastructure propels the growth of the market in the region. Asia Pacific is promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Huge population base in countries such as China and India offers tremendous market opportunities for the etanercept biosimilar market. North America is third major contributor for the market in forecast period and is expected to grow at rapid pace, due to presence of strong clinical pipeline.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD XX Million |
|
Revenue Forecast In 2031 |
USD XX Million |
|
Growth Rate CAGR |
CAGR of 17.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Brand, By Applications, By Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Avesthagen, Cipla, LG Life Sciences, Protalix Biotherapeutics, BioXpress Therapeutics, Sandoz, Celltrion, Teva Pharmaceutical Industries, Pfizer, Samsung Bioepis, mAbxience, and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Etanercept Biosimilar Market Snapshot
Chapter 4. Global Etanercept Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Brand Estimates & Trend Analysis
5.1. By Brand & Market Share, 2021 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Brand:
5.2.1. Benepali
5.2.2. Brenzys
5.2.3. Erelzi
5.2.4. Eticovo
5.2.5. Nepexto
5.2.6. Rymti
5.2.7. Others (Products approved in developing countries & pipeline products)
Chapter 6. Market Segmentation 2: By Applications Estimates & Trend Analysis
6.1. By Applications & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Applications:
6.2.1. Rheumatoid arthritis
6.2.2. Juvenile rheumatoid arthritis
6.2.3. Psoriatic arthritis
6.2.4. Plaque psoriasis
6.2.5. Ankylosing spondylitis
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. By Distribution Channel & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Distribution Channel:
7.2.1. Hospital Pharmacy
7.2.2. Online Pharmacy
7.2.3. Retail Pharmacy
7.2.4. Other Direct Distribution Channels
Chapter 8. Etanercept Biosimilar Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Brand, 2024 - 2034
8.1.2. North America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Applications, 2024 - 2034
8.1.3. North America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2024 - 2034
8.1.4. North America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2024 - 2034
8.2. Europe
8.2.1. Europe Etanercept Biosimilar Market revenue (US$ Million) By Brand, 2024 - 2034
8.2.2. Europe Etanercept Biosimilar Market revenue (US$ Million) By Applications, 2024 - 2034
8.2.3. Europe Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2024 - 2034
8.2.4. Europe Etanercept Biosimilar Market revenue (US$ Million) by country, 2024 - 2034
8.3. Asia Pacific
8.3.1. Asia Pacific Etanercept Biosimilar Market revenue (US$ Million) By Applications, 2024 - 2034
8.3.2. Asia Pacific Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2024 - 2034
8.3.3. Asia Pacific Etanercept Biosimilar Market revenue (US$ Million) by country, 2024 - 2034
8.4. Latin America
8.4.1. Latin America Etanercept Biosimilar Market revenue (US$ Million) By Brand, (US$ Million)
8.4.2. Latin America Etanercept Biosimilar Market revenue (US$ Million) By Applications, (US$ Million)
8.4.3. Latin America Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2024 - 2034
8.4.4. Latin America Etanercept Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2024 - 2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Etanercept Biosimilar Market revenue (US$ Million) By Brand, (US$ Million)
8.5.2. Middle East & Africa Etanercept Biosimilar Market revenue (US$ Million) By Applications, (US$ Million)
8.5.3. Middle East & Africa Etanercept Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2024 - 2034
8.5.4. Middle East & Africa Etanercept Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2024 - 2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Samsung Bioepis
9.2.2. Sandoz (Novartis generics division)
9.2.3. Mylan
9.2.4. Lupin
9.2.5. YL Biologics
9.2.6. Cipla
9.2.7. Sunshine Guojian Pharmaceutical
9.2.8. LG Chem
9.2.9. Hanwha Chemical
9.2.10. Merck
9.2.11. Biogen
9.2.12. Shanghai CP Guojian Pharmaceutical
9.2.13. AYUMI Pharmaceutica
9.2.14. Other prominent players
Global Etanercept Biosimilar Market Outlook By Brand
Global Etanercept Biosimilar Market Outlook By Application
Global Etanercept Biosimilar Market Outlook By Distribution Channel
Global Etanercept Biosimilar Market Outlook By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
